Discovery channel feed – Endpoints News

Discovery channel feed

Diving deep into AMD, Yale researchers pinpoint cell types drug developers should pay special attention to

6 years ago

Can CBD temper Parkinson's-related psychosis? UK researchers will look for answers in PhII study

6 years ago

What does Nobel-quality research look like in action? Researchers recount the Bill Kaelin experiment

6 years ago

Trio wins Nobel Prize for Medicine for 'fundamental' discovery

6 years ago

Canadian star researcher Brendan Frey brandishes Deep Genomics' first AI-discovered drug

6 years ago

Explosion, fire rip Russian research facility housing smallpox, Ebola

6 years ago

Versant-backed Chinook gets a $65M launch round for its discovery quest in a resurgent kidney field

6 years ago

How does TDP-43 bog up the brains of ALS, FTLD patients? AC Immune enlists Penn scientists to find out

6 years ago

Bayer’s $240M upfront for BlueRock acquisition puts them in the high rollers club for preclinical biotech buyouts

6 years ago

Adrian Hayday refutes challenge on influential autoantibody paper by Karolinska scientists

6 years ago

PD-L1, CD47 and now CD24? Star Stanford I/O scientist Irv Weissman points to a ‘major’ new cancer target

6 years ago

Wellcome Trust joins warning for no-deal Brexit, calls on Boris Johnson to cast R&D vision

6 years ago

PACT Pharma says it's perfected the tech to select neoantigens for personalized therapy — now onto the clinic

6 years ago

Genentech inks its latest discovery deal — this time turning to RNA upstart Skyhawk

6 years ago

Supercharging CAR-T with cancer vaccine, MIT team spotlights some new tech underpinning Darrell Irvine's startup

6 years ago

Just how much would no-deal Brexit harm biomedical science? Researchers speak out

6 years ago

GSK's Barron joins hands with Doudna, Weissman to deploy CRISPR tech in drug discovery

6 years ago

Russian scientist plans to one-up Jiankui He in creating his own CRISPR babies — Nature

6 years ago

Add one fatal flaw to Jiankui He's litany of mistakes in CRISPR baby debacle

6 years ago

A new interleukin target for NASH spawns Singaporean biotech steered by well known players

6 years ago

Can a little known drug in AstraZeneca's pipeline make a comeback as a PARP add-on? Yale scientists explain how

6 years ago

Genentech lines up a new autoimmune R&D alliance on a 'potentially transformative' tech

6 years ago

Can we stop cancer cells from evolving and developing drug resistance? British scientists take a leaf out of the HIV playbook

6 years ago

Tessa showcases preclinical promise of 'all-in-one' add-on to its cancer cell therapy, in march to the clinic

7 years ago

First page Previous page 4 5 678 9 10 Next page Last page